Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 7/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16181580 | 0.90 | PLA2G4A (0.52) | PLA2G4APLA2G2ASMPD1 | |
| SCHEMBL21132793 | 0.72 | PLA2G2A (0.50) | PLA2G4APLA2G2A | |
| SCHEMBL18826517 | 0.72 | PLA2G4A (0.44) | PLA2G4APLA2G2ATP53CYP1A2CYP2D6 | |
| SCHEMBL16575579 | 0.69 | PLA2G2A (0.70) | PLA2G4APLA2G2A | |
| SCHEMBL19928630 | 0.69 | FABP3 (0.41) | PLA2G4APLA2G2ATP53CYP1A2CYP2D6 | |
| SCHEMBL12313943 | 0.69 | FABP3 (0.41) | PLA2G4APLA2G2ATP53CYP1A2CYP2D6 | |
| SCHEMBL3765894 | 0.68 | PLA2G4A (0.79) | PLA2G4ATP53CYP1A2CYP2D6MAPT | |
| SCHEMBL21060658 | 0.68 | PLA2G4A (0.79) | PLA2G4ATP53CYP1A2CYP2D6MAPT | |
| SCHEMBL30073256 | 0.68 | PLA2G4A (0.79) | PLA2G4ATP53CYP1A2CYP2D6MAPT | |
| SCHEMBL16085651 | 0.67 | PLA2G4A (0.66) | PLA2G4ATP53CYP1A2CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | FURIN, IAPP, APP | PLA2G4A 2883/4885PLA2G2A 3388/4885TP53 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.